Amylyx Pharmaceuticals Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- amylyx.com
- Founded
- 2013
- Employees
- 251-1K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $798,008 |
| FY2023 | $994,264 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Biogen U.s. Corporation | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Acorda Therapeutics, Inc. | — | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Genzyme | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Catalyst Pharmaceuticals, Inc. | Coral Gables, FL | 325412 Pharmaceutical Preparation Manufacturing |
| Mirum Pharmaceuticals, Inc. | San Mateo, CA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Amylyx Pharmaceuticals Inc., doing business as Amylyx, is a biopharmaceutical company that provides pharmaceutical products to the U.S. federal government, primarily through the Department of Veterans Affairs (VA). The company specializes in developing treatments for neurodegenerative diseases, with a focus on amyotrophic lateral sclerosis (ALS). Amylyx's primary product supplied to the government is RELYVRIO, an FDA-approved treatment for ALS containing sodium phenylbutyrate and taurursodiol. As a self-certified small disadvantaged business, Amylyx has secured multiple contract vehicles with the VA to facilitate the distribution of its pharmaceutical products to veterans across the country.
The majority of Amylyx's federal contract awards are for the provision of RELYVRIO to various Veterans Integrated Service Networks (VISNs) within the Veterans Health Administration (VHA). These awards are typically firm-fixed-price delivery orders ranging from approximately $10,000 to $350,000, with performance periods generally spanning a few months. The place of performance for these contracts is usually Cambridge, Massachusetts, where Amylyx is headquartered. The company has received multiple awards from VISN 20 and VISN 21, indicating a strong presence in supplying ALS treatment to VA medical facilities in the western United States. No subcontractors or set-aside designations were identified in the provided contract information, suggesting that Amylyx directly fulfills these orders as a prime contractor.
Amylyx holds several significant Indefinite Delivery Vehicles (IDVs) with the federal government. The company was awarded a Federal Supply Schedule (FSS) contract (36F79723D0136) by the VA National Acquisition Center, with a ceiling value of $225,000 and a performance period through May 31, 2028. This multiple-award contract allows for the procurement of drugs, pharmaceuticals, and hematology-related products. Additionally, Amylyx has two Blanket Purchase Agreements (BPAs) with the VA. The first (36E79723A0017) has a ceiling value of $50,000 and runs through June 11, 2024, specifically for the procurement of RELYVRIO. The second BPA (36E79723A0009), also valued at $50,000, expired on June 27, 2023. These contract vehicles enable VA facilities nationwide to efficiently order RELYVRIO and other Amylyx products as needed. The company also held an interim agreement (36F79723D010E) under FSS Schedule 65 I B for drugs and pharmaceuticals, which had a ceiling value of $25,000 and expired on May 31, 2023. These IDVs demonstrate Amylyx's established relationship with the VA and its commitment to providing ALS treatment to veterans through various contractual mechanisms.
Quick answers
Is Amylyx Pharmaceuticals Inc. registered in SAM.gov?
Amylyx Pharmaceuticals Inc.'s SAM.gov registration expired on October 8, 2024.
What is Amylyx Pharmaceuticals Inc.'s CAGE code?
Amylyx Pharmaceuticals Inc.'s CAGE code is 7ZTZ1, and its Unique Entity ID (UEI) is Y5H6VQL1KHQ1.
How much has Amylyx Pharmaceuticals Inc. received in federal contracts?
Federal contracts obligated $1,792,272 to Amylyx Pharmaceuticals Inc. in fiscal years 2023 through 2027.
What is Amylyx Pharmaceuticals Inc.'s most recent federal award?
Amylyx Pharmaceuticals Inc.'s most recent federal contract award is Relyvrio - pharmaceutical (36C26024F0268), from Veterans Integrated Service Network 20 (VHA), on April 1, 2024.
On GovTribe
See Amylyx Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors